3 things to know about the US’ potential flu vaccination shortage

In June, the CDC recommended against using AstraZeneca’s nasal flu vaccine, FluMist, citing a lack of evidence regarding the vaccine’s efficacy. FluMist’s absence from the American market is causing some physicians to worry about a potential flu vaccine shortage.

Advertisement

Here are three things to know.

  1. Fu Mist vaccine accounted for 8 percent — 14 million units — of the country’s vaccination stock, according to Shimona Thakrar, MD, pediatrician at Scott and White Memorial Hospital in Temple, Texas.
  2. While drug manufacturers are working quickly to prepare for flu season, FluMist’s absence from the market may increase demand for the flu shot and lead to shortages.
  3. Dr. Thakrar recommends patients get a flu shot as early as possible to guarantee vaccination. The shot vaccine offers protection for about a year. Flu season usually runs October through May, peaking in December and January.

More articles on supply chain:

FDA: Drug companies abuse citizen petitions to block generic competition
Sen. Chuck Grassley to EpiPen maker: Why the 400% price hike?
Supply chain tip of the week: Replenish your inventory the right way

 

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.